rMenB+OMV NZ

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prevention of the Meningococcal Disease

Conditions

Prevention of the Meningococcal Disease

Trial Timeline

Aug 1, 2013 → Apr 1, 2014

NCT ID

NCT01911221

About rMenB+OMV NZ

rMenB+OMV NZ is a phase 3 stage product being developed by Novartis for Prevention of the Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01911221. Target conditions include Prevention of the Meningococcal Disease.

What happened to similar drugs?

9 of 20 similar drugs in Prevention of the Meningococcal Disease were approved

Approved (9) Terminated (0) Active (11)

✅RaltegravirMerckApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Boostrix + Placebo (Saline)NovartisApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01911221	Phase 3	Completed	Aug 1, 2013	Apr 1, 2014	Prevention of the Meningococcal Disease
NCT01139021	Phase 3	Completed	Jun 1, 2010	Sep 1, 2011	Meningococcal Disease

Competing Products

20 competing products in Prevention of the Meningococcal Disease

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44